1,552
Participants
Start Date
October 9, 2014
Primary Completion Date
October 4, 2017
Study Completion Date
October 4, 2017
LF111 (drospirenone)
One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
NYU School of Medicine, New York
University of Pennsylvania School of Medicine, Philadelphia
Clinical Research Of Philadelphia, Philadelphia
Johns Hopkins School of Medicine, Baltimore
Eastern Virginia Medical School, Norfolk
Hawthorne Medical Research, Inc., Winston-Salem
Wake Research Associates, Raleigh
Eastern Carolina Women's Center, New Bern
Fellows Research Alliance, Inc., Bluffton
Fellows Research Alliance, Inc., Savannah
Miami Research Associates, Miami
Segal Institute for Clinical Research, North Miami
Comprehensive Clinical Trials, LLC, West Palm Beach
Altus Research, Lake Worth
Meridien Research - Tampa, Tampa
Meridien Research - St. Petersburg, St. Petersburg
Alabama Clinical Therapeutics, Birmingham
Bluegrass Clinical Research, Inc, Louisville
Columbus Obstetricians-Gynecology, Inc./Radiant Research, Inc., Columbus
University of Cincinnati, Cincinnati
Beyer Research, Kalamazoo
Practice Research Organization, Dallas
TMC Life Research, Inc., Houston
Advanced Research Associates, Corpus Christi
Downtown Women's Health Care, Denver
Horizons Clinical Research Center, LLC, Denver
Rosemark WomenCare Specialists, Idaho Falls
Physicians' Research Options, Draper
Physicians' Research Options, Pleasant Grove
Southwest Clinical Research, Albuquerque
Women's Health Care Research Corp., San Diego
WCCT Global, Costa Mesa
Anaheim Clinical Trials, LLC, Anaheim
Seattle Women's Health, Research, Gynecology, Seattle
Stamford Therapeutics Consortium, Stamford
Lawrence OBGYN Clinical Research, LLC, Lawrenceville
The Center for Women's Health & Wellness, LLC, Plainsboro
Chemo France
INDUSTRY
Laboratories Leon Farma, S.A.
INDUSTRY